Clinical Trials Logo

Lung Cancer Stage III clinical trials

View clinical trials related to Lung Cancer Stage III.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04364776 Active, not recruiting - Lung Cancer Clinical Trials

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Start date: January 15, 2020
Phase:
Study type: Observational

The introduction of maintenance immunotherapy with the anti PD-L1 inhibitor durvalumab opened a new therapeutic window for stage III NSCLC patients who achieve at least stable disease after chemo-radiation, as shown by the randomized phase 3 PACIFIC study. However, still half of the patients do progress at 12 months (up to 70% at 18 months). In this study, the investigators aim to test a non-invasive image-based approach, namely a "radiomics" platform, as a tool to define a higher or lower likelihood of response to chemo-radiation and durvalumab. For this purpose, we will retrospectively and prospectively collect and analyze a cohort of at least 70 stage III NSCLC patients treated with CT-RT followed by maintenance durvalumab.

NCT ID: NCT04003246 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Start date: April 3, 2020
Phase: Phase 2
Study type: Interventional

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT ID: NCT03141359 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Start date: May 12, 2017
Phase: Phase 2
Study type: Interventional

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation with or without consolidation chemotherapy. A total of 60 subjects will be enrolled to this study over a 4 year accrual period.